Actionable news
All posts from Actionable news
Actionable news in ABIO: ARCA biopharma, Inc.,

Neos receives FDA Approval; ​Egalet EGLT issued CRL - shares lose 18%; Sangamo SGMO offering

Price and Volume Movers

Egalet Corporation (Nasdaq: EGLT) announced that the FDA issued a Complete Response Letter (CRL) for its prior approval supplement of OXAYDO tablets C-II in 10 mg and 15 mg dosage strengths for the management of acute and chronic, moderate to severe pain. The FDA has requested more information regarding the effect of food on OXAYDO 15 mg and the intranasal abuse-deterrent properties of OXAYDO 10 and 15 mg. Shares closed down 18% to $2.36.

Neos Therapeutics, Inc. (Nasdaq:NEOS) announced late Monday following the after-hours session that the FDA has approved Cotempla XR-ODT for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients 6 to 17 years old. Shares closed down 11% to $8.00 on profit-taking after spiking during the pre-market session. Shares had rallied as high as $9.56 during Monday’s session in anticipation of the approval.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced that it has commenced an underwritten public offering of shares of its common stock. Shares are currently...